Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Clin Cancer Res. 2008 Nov 15;14(22):7340–7347. doi: 10.1158/1078-0432.CCR-08-0642

Figure 6. Pharmacologic inhibition of HDAC6 impedes cell motility and migration of ovarian cancer cells.

Figure 6

A Plates of confluent SKOV-3 cells either mock or NK84 treated (10 μM) were examined by phase-contrast microscopy at the time of removal by scratching (0 hours) and 5 hours later. B, Analysis of the number of SKOV-3 cells spreading across the wound; results are means ± SD of three independent experiments. C, an equivalent number (2.5 × 104) of SKOV-3 or ES-3 cells mock-treated or treated with 10 μM of NK84 HDAC6 inhibitor were seeded in migration chambers and migrating cells were counted per each condition 8 hours thereafter. Three different fields of cells for each condition were counted at 40X. Each assay was performed in triplicate. Shown are means ± SD of migrating cells per microscopic field. D, representative example of migration assay conducted on mock or NK84-treated SKOV-3 cells.